Related Experiment Videos
Methotrexate for rejection prophylaxis after heart transplantation
D O Taylor1, S L Olsen, R D Ensley
1Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City 84132, USA.
Summary
Adding methotrexate to quadruple-drug immunotherapy after heart transplantation did not significantly reduce rejection rates. This study found no added benefit from methotrexate, with similar toxicity and infection rates compared to standard therapy.
Area of Science:
- Immunology
- Transplantation Medicine
- Pharmacology
Background:
- Quadruple-drug induction immunotherapy (OKT3, cyclosporine, azathioprine, prednisone) reduces heart transplant rejection but causes neurotoxicity.
- Vincristine addition improves outcomes but is limited by neurotoxicity.
Purpose of the Study:
- To evaluate if adding methotrexate to quadruple therapy could decrease rejection incidence post-heart transplant.
- To assess if methotrexate offers reduced toxicity compared to vincristine.
Main Methods:
- A randomized trial involving 36 heart transplant recipients.
- Group 1: Quadruple therapy (n=19). Group 2: Quadruple therapy plus methotrexate (n=17).
- Methotrexate administered weekly for 8 weeks post-OKT3 therapy, dosed by WBC count.
Main Results:
- Rejection indexes were similar between groups (days to first rejection, treated episodes, biopsy scores).
- No significant differences in toxicity or infection rates were observed.
- 11 patients completed methotrexate protocol at a mean dose of 8.6 mg/week.
Conclusions:
- An 8-week course of methotrexate provides no significant benefit to quadruple-drug immunotherapy in heart transplant recipients.
- While toxicity was minimal, methotrexate did not enhance the efficacy of standard quadruple therapy.